Yelak Biru, President and Chief Executive Officer at International Myeloma Foundation, shared a post on X:
“UK grants first approval for Blenrep in multiple myeloma:
Dr. Joseph Mikhael, highlighted the importance of accessible combination therapies like Blenrep in community settings where many patients are treated, noting their potential to extend remission and survival.”
Rakesh Popat, Associate Professor at shared this post on X, adding:
“MHRA first to approve Bela Vd and Bela Pd for relapsed myeloma.
UK myeloma docs: remember to enrol into the ProMMise trial of Bela-Vd so we can build the evidence to remove ocular examinations.”
